Pharmacological Management of Idiopathic Pulmonary Fibrosis Chapter uri icon

abstract

  • Idiopathic pulmonary fibrosis (IPF) is a common interstitial lung disease (ILD) caused by environmental exposures, infections, or traumatic injuries and subsequent epithelial damage. Since IPF is a progressively fatal disease without remission, treatment is both urgent and necessary. The two medications indicated solely for treatment include the tyrosine kinase inhibitor nintedanib (Ofev) and the anti-fibrotic agent pirfenidone (Esbriet). This chapter discusses in detail the current treatment options for clinical management of IPF, specifically the mentioned two pharmacotherapeutic agents that decrease physiological progression and likely improve progression-free survival. The chapter also discusses the evolution of drug therapy in IPF management and the drawbacks and limitations learned throughout historical trials and observational studies.

author list (cited authors)

  • Panahi, L., Udeani, G., Scott Tenpas, A., Ofili, T., Marie Aguilar, E., Burchard, S., ... Vara, N.

citation count

  • 0

complete list of authors

  • Panahi, Ladan||Udeani, George||Scott Tenpas, Andrew||Ofili, Theresa||Marie Aguilar, Elizabeth||Burchard, Sarah||Ruth Ritenour, Alexandra||Jacob Chennat, April||Ahmed, Nehal||Atphaisit, Chairat||Chi, Crystal||Cruz III, Jesus||D. Deleon, Monica||Lee, Samantha||Mayo, Zack||Mcbeth, Mackenzie||Morales, Mariel||N. Nwosu, Jennifer||Palacios, Kelly||M. Pena, Jaycob||Vara, Nitza

Book Title

  • Idiopathic Pulmonary Fibrosis

publication date

  • October 2022